Skip to main content
SpringerLink
Log in

Single agent chemotherapy in the management of ovarian carcinoma

  • Chapter
Ovarian Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 23))

Abstract

Ovarian cancer is comprised of celomic epithelial cancers, germ cell neoplasms, stromal cancers, and certain other rare lesions. Celomic epithelial lesions account for over 85% of all ovarian cancers; therefore, most data concerning the management of ovarian cancer relate to studies in patients with ovarian carcinoma arising from celomic epithelium. Discussion of single-agent systemic therapy will thus relate only to these lesions of celomic epithelial origin (henceforward referred to simply as ovarian carcinoma).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kauppila A, Vierikko P, Kivinen S, Stenback F, Vihko R: Clinical significance of estrogen and progestin receptors in ovarian cancer. Obstet Gynecol 61:320–326, 1983.

    PubMed  CAS  Google Scholar 

  2. Pollow K, Schmidt-Matthiesen A, Hoffman G, Schweikhart G, Kreinberg R, Manz B, Grill HJ: 3H-estradiol and 3H-R5020 binding in cytosols of normal and neoplastic human ovarian tissue. Int J Cancer 31:603–608, 1983.

    PubMed  CAS  Google Scholar 

  3. DeVita VT, Wasserman TH, Young RC, Carter SK: Perspectives on research in gynecologic oncology. Cancer 38:509–525, 1976.

    PubMed  Google Scholar 

  4. Malkasian G, Decker D, Green S, Edmonson J, Jeffries J, Webb M: Treatment of recurrent and metastatic carcinoma of the cervix: Comparison of doxorubicin with a combination of vincristine and 5-fluorouracil. Gynecol Oncol 11:235–239, 1981.

    PubMed  Google Scholar 

  5. Cavin J, Geisler H: Treatment of advanced, unresectable cervical carcinoma already subjected to complete irradiation therapy. Gynecol Oncol 6:256–260, 1978.

    Google Scholar 

  6. Brenner F, Forastiere A, Rosenchein N, Jones H, Dillon M, Grumbine F, Tipping S, Aisner J, Burnett L, Greco F, Wiernik P: A Phase II study of spirogermanium in patients with advanced carcinomas of the ovary and cervix. Proc ASCO 1:115, 1982.

    Google Scholar 

  7. Thigpen T, Ehrlich C, Blessing J: Phase II trial of maytansine in treatment of advanced or recurrent squamous cell carcinoma of the cervix. A gynecologic oncology group study. Proc ASCO 21:424, 1980.

    Google Scholar 

  8. Conroy J, Blessing J, Lewis G, Mangan C, Hutch K, Wilbanks G: Phase II trial of ICRF-159 in treatment of advanced squamous cell carcinoma of the cervix. Proc ASCO 21:423, 1980.

    Google Scholar 

  9. Rossof AH, Drukker BH, Talley RW, Torres J, Bonnett J, Brownlee RW: Randomized evaluation of chlorambucil and melphalan in advanced ovarian cancer. Proc AACR-ASCO 17:300, 1976.

    Google Scholar 

  10. Piver MS, Barlow JJ, Chung WS: High-dose cyclophosphamide for recurrent or progressive ovarian adenocarcinoma. Cancer Chemother Rep 59:1157–1158, 1975.

    PubMed  CAS  Google Scholar 

  11. Hubbard SM, Barkes P, Young RC: Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. Cancer Treatment Rep 62:1375–1377, 1978.

    CAS  Google Scholar 

  12. Stanhope CR, Smith JP, Rutledge F: Second trial drugs in ovarian cancer. Gynecol Oncol 5:52–58, 1977.

    PubMed  CAS  Google Scholar 

  13. Malkasian GD Jr: Chemotherapy for ovarian cancer. Med Clin North Amer 58:779–792, 1974.

    Google Scholar 

  14. Twiggs LB, Morrow CP: Treatment of advanced ovarian carcinoma with high-dose cyclophosphamide after failure on melphalan. Cancer Treatment Rep 61:1369–1371, 1977.

    CAS  Google Scholar 

  15. Bruckner HW, Ratner LH, Cohen CJ, Wallach R, Kabakow B, Greenspan EM, Holland JF: Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (11) after failure of initial chemotherapy. Cancer Treatment Rep 62:1021–1023, 1978.

    CAS  Google Scholar 

  16. Piver MS, Barlow JJ, Yazizi R, Blumenson LE: Melphalan chemotherapy in advanced ovarian carcinoma. Obstetr Gynecol 51:352–356, 1978.

    CAS  Google Scholar 

  17. Fisher RI, Young RC: Advances in the staging and treatment of ovarian cancer. Cancer 39:967–972, 1977.

    PubMed  CAS  Google Scholar 

  18. Thigpen T: The chemotherapy of epithelial ovarian cancer. In: Ballon Sc, ed, Gynecologic Oncology: Controversies in Cancer Treatment, GK Hall, 1981, pp. 272–294.

    Google Scholar 

  19. Young RC, Hubbard SH, DeVita VT: The chemotherapy of ovarian carcinoma. Cancer Treat Rev 1:99–110, 1974.

    Google Scholar 

  20. Young RC: Chemotherapy of ovarian cancer: past and present. Sem Oncol 2:267–276, 1975.

    CAS  Google Scholar 

  21. Thigpen JT, Lagasse L, Homesley H, Blessing JA: Cisplatinum in the treatment of advanced or recurrent adenocarcinoma of the ovary: a phase II study of the Gynecologic Oncology Group. Amer J Clin Oncol 6:431–435, 1983.

    CAS  Google Scholar 

  22. Young RC, Von Hoff DD, Gormley P, Makuch R, Cassidy J, Howser D, Bull JM: Cis-Dichlorodiammineplatinum (11) for the treatment of advanced ovarian cancer. Cancer Treat Rep 63:1539–1544, 1979.

    PubMed  CAS  Google Scholar 

  23. Bagley CM, Young RC, Canellos GP, DeVita VT: Treatment of ovarian carcinoma: possibilities for progress. New Eng J Med 287:856–862, 1972.

    PubMed  Google Scholar 

  24. Fisher RI, Young RC: Chemotherapy of ovarian cancer. Surg Clin N Amer 58:143–150, 1978.

    PubMed  CAS  Google Scholar 

  25. Taetle R, Dickman PS, Feldman PS: Pulmonary histopathologic changes associated with melphalan therapy. Cancer 42:1239–1245, 1978.

    PubMed  CAS  Google Scholar 

  26. Einhorn N: Acute leukemia after chemotherapy. Cancer 44:444–447, 1978.

    Google Scholar 

  27. Rosner F: Multiple myeloma and acute leukemia: a review of 104 cases. Proc AACR-ASCO 20:299, 1979.

    Google Scholar 

  28. Papavasilion C, Pappas J, Aravantinos D, Kaskarelis D: Treatment of cervical carcinoma with adriamycin combined with methotrexate. Cancer Treat Rep 62:1005–1006, 1979.

    Google Scholar 

  29. Young RC et.al: Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecol Oncol 2:489–497, 1974.

    PubMed  CAS  Google Scholar 

  30. Alberts DS, Chang SY, Chen HSG, Evans TL, Moon TE: Variability of melphalan absorption in man. Proc AACR-ASCO 19:334, 1978.

    Google Scholar 

  31. Brady L, et al.: Radiotherapy, chemotherapy and combined therapy in stage III epithelial ovarian cancer. Cancer Clin Trials 2:111–120, 1979.

    Google Scholar 

  32. Blom J, Park R, Blessing J: Treatment of Women with disseminated and recurrent ovarian carcinoma with single and multichemotherapeutic agents. Proc AACR-ASCO 19:338, 1978.

    Google Scholar 

  33. Omura G, et al.: A randomized trial of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in advanced ovarian adenocarcinoma. Proc AACR-ASCO 20:358, 1979.

    Google Scholar 

  34. Smith JP, Rutledge F: Chemotherapy in the treatment of cancer of the ovary. Amer J Obstetr Gynecol 107:691–703, 1970.

    CAS  Google Scholar 

  35. Wallach RC et al.: Thiotepa chemotherapy for ovarian carcinoma: influence of remission and toxicity on survival. Obstetr Gynecol 25:475–478, 1965.

    Google Scholar 

  36. Parker RT, Parker CH, Wilbanks GD: Cancer of the ovary: survival studies based upon operative therapy, chemotherapy, and radiotherapy. Amer J Obstetr Gynecol 108:878–888, 1970.

    CAS  Google Scholar 

  37. Krakoff IH: Nephrotoxicity of cis-dichlorodiammineplatinum (11). Cancer Treat Rep 63:1523–1525, 1979.

    PubMed  CAS  Google Scholar 

  38. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozenceverz M, Young RC, Muggia FM: Toxic effects of cis-dichlorodiammineplatinum (11) in man. Cancer Treat Rep 63:1527–1532, 1979.

    Google Scholar 

  39. Wiltshaw E, Kroner T: Phase II of dischlorodiammineplatinum (11) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60:55–60, 1976.

    PubMed  CAS  Google Scholar 

  40. Rossof AH, Talley RW, Stephens R, Thigpen T, Samson MK, Groppe C, Eyre HJ, Fisher R: Phase II evaluation of cis-dichlorodiammineplatinum (11) in advanced malignancies of the genitourinary and gynecologic organs. Cancer Treat Rep 63:1557–1564, 1979.

    PubMed  CAS  Google Scholar 

  41. Bruckner HW, Cohen CJ, Deppe G et al.: Chemotherapy of gynecologic tumors with platinum II. J Clin Hematol Oncol 7:619–632, 1977.

    Google Scholar 

  42. Bruckner HW, Cohen CJ, Wallach RC et al.: Treatment of advanced ovarian cancer with cis-dichorodiammineplatinum (11): poor-risk patients with intensive prior therapy. Cancer Treat Rep 62:555–558, 1978.

    PubMed  CAS  Google Scholar 

  43. Piver MS, Barlow JJ, Lele SB, et al.: Cisdichlorodiammineplatinum (11) as third-line chemotherapy in advanced ovarian adenocarcinoma. Cancer Treat Rep 62:559–560, 1978.

    PubMed  CAS  Google Scholar 

  44. Wiltshaw E, Subramatian S, Alexopoulos C, Barker GH: Cancer of the ovary: a summary of experience with cisdichlorodiammineplatinum (11) at the Royal Marsden Hospital. Cancer Treat Rep 63:1545–1548, 1979.

    PubMed  CAS  Google Scholar 

  45. DiMarco A, Zunino F, Silvestrini R, Gambarricu C, Gambetto RA: Interaction of some daunomycin derivatives with deoxyribonucleic acid and their biological activity. Biochem Pharmacol 20:1323–1328, 1971.

    CAS  Google Scholar 

  46. Barlow JJ, Piver MS, Chuanz JT et al.: Adriamycin and bleomycin alone and in combination in gynecologic cancer. Cancer 32:735–741, 1973.

    PubMed  CAS  Google Scholar 

  47. DePalo GM, DeLena M, DiRe F, Luciani L, Valagussa P, Bonadonna G: Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary. Surg Gynecol Obstetr 141:899–902, 1975.

    CAS  Google Scholar 

  48. Bonadonna G, Beretta G, Tancini G et al.: Adriamycin studies at the Instituto Nazionale Tumori, Milam. Cancer Chemother Rep Part 3, Vol 6:231–245, 1975.

    Google Scholar 

  49. Blum RH, Carter SK: Adiamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 80:249, 1974.

    PubMed  CAS  Google Scholar 

  50. McGuire WP, Young RC: Ovarian cancer. In Staquet MJ(ed),Randomized Trials in Cancer: a Critical review by Sites. New York, Raven Press, 1978.

    Google Scholar 

  51. Worzalla JE, et al.: Metabolism of hexamethylmelamine-ring-14C in rats and man. Cancer Res 34:2669–2674, 1974.

    PubMed  CAS  Google Scholar 

  52. Takita H, Didolkar MS: Effects of hexamethylmelamine on small cell carcinoma of the lung. Cancer Chemothera Rep 58:371–374, 1974.

    CAS  Google Scholar 

  53. Wamplu GL, Mellette SJ, Kumperming M, Regelson W: Hexamethylmelamine in the treatment of advanced cancer. Cancer Chemother Rep 56:505–514, 1972.

    PubMed  Google Scholar 

  54. Wilson WL, Bisel HF, Cole D, Rochlin D, Ramurez G, Madden R: Prolonged low-dosage administration of hexamethylmelamine. Cancer 25:568–570, 1970.

    PubMed  CAS  Google Scholar 

  55. Weiss RB: The role of hexamethylmelamine in advanced ovarian carcinoma treatment. Gynecol Oncol 12:141–149, 1981.

    PubMed  CAS  Google Scholar 

  56. Wharton JT, Rutledge F, Smith JP, Herson J, Hodge MP: Hexamethylmelamine: an evaluation of its tole in the treatment of ovarian cancer. Amer J Obstetr Gynecol 133:833–844, 1979.

    CAS  Google Scholar 

  57. Wilson Wl, Schoeder Jm, Bisel HF, Mragek, Hummel RP: Phase II study of hexamethylmelamine. Cancer 23:132–136, 1969.

    PubMed  CAS  Google Scholar 

  58. Stanhope CR, Smith JP, Rutledge F: Second trial drugs in ovarian cancer. Gynecol Oncol 5:52–58, 1977.

    PubMed  CAS  Google Scholar 

  59. Johnson BL, Fisher RI, Bender RA, DeVita VT, Chabner BA, Young RC: Hexamethylmelamine in alkylating agent resistant ovarian cancer. Cancer 42:2157–2161, 1978.

    PubMed  CAS  Google Scholar 

  60. Bonomi PD, Mladineo J, Morris B, Wilbanks G, Slayton RE: Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents. Cancer Treat Rep 63:137–138, 1979.

    PubMed  CAS  Google Scholar 

  61. Bolis G, D’Inealci M, Belloni C, Mangioni C: Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin. Cancer Treat Rep 63:1375–1377, 1979.

    PubMed  CAS  Google Scholar 

  62. Omura GA, Greco FA, Birch R: Hexamethylmelamine in mustard-resistant ovarian adenocarcinoma. Cancer Treat Rep 65:530–531, 1981.

    PubMed  CAS  Google Scholar 

  63. Smith JP, Rutledge F: Random study of hexamethylmelamine, 5-fluorouracil and melphalan in treatment of advanced carcinoma of the ovary. Natl Cancer Instit Monogr 42:169–172, 1975.

    CAS  Google Scholar 

  64. Ansfield FJ, Schroeder JM, Curreri AR: Five years clinical experience with 5-fluorouracil. JAMA 181:295–299, 1962.

    PubMed  CAS  Google Scholar 

  65. Malkasian GD, Decker DG, Mussey E, et al.: Observations on gynecologic malignancy treated with 5-fluorouracil. Am J Obstet Gynecol 100:1012–1017, 1968.

    PubMed  Google Scholar 

  66. Vaitkevicius VK, Brennen HJ, Beckett VL, et al.: Clinical evaluation of cancer chemotherapy with 5-fluorouracil. Cancer 14:131–135, 1961.

    PubMed  CAS  Google Scholar 

  67. Kennedy BJ, Theologides A: The role of 5-fluorouracil in malignant disease. Ann Intern Med 55:719–730, 1961.

    PubMed  CAS  Google Scholar 

  68. Young CW, Ellison RR, Sullivan RD, et al.: The clinical evaluation of 5-fluorouracil and 5-fluoro-2′-Deoxyuridine in solid tumors in adults. A progress report. Cancer Chemother Rep 6:17–20, 1960.

    PubMed  CAS  Google Scholar 

  69. Field JG: 5-Fluorouracil (NSC-19893) treatment of advanced cancer in ambulatory patients. Cancer Chemother Rep 33:45–50, 1963.

    PubMed  CAS  Google Scholar 

  70. Hall BE, Good JW: Treatment of far advanced cancer with 5-fluorouracil used alone and in combination with irradiation. Incidence and duration of remission and survival-time data in 223 patients. Cancer Chemother Rep 16:369–375, 1962.

    PubMed  CAS  Google Scholar 

  71. Jacobs EM, Reeves WJ, Wood DA, et al.: Treatment of cancer with weekly intravenous 5-fluorouracil. Cancer 27:1302–1305, 1971.

    PubMed  CAS  Google Scholar 

  72. Sullivan RD, Miller E, Zurek WZ, et al.: Re-evaluation of metrexate as an anticancer drug. Surg Gynecol Obstet 125:819–824, 1967.

    PubMed  CAS  Google Scholar 

  73. Greenspan EM, Bruckner HW: Comparison of regression induction with thio-tepa or methotrexate in bulky stage IIIB ovarian carcinoma. J Natl Cancer Instit Monogr.

    Google Scholar 

  74. Parker LM, Griffiths CT, Yankee RA, Knapp RC, Canellos GP: High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study. Cancer Treat Rep 63:275–279, 1979.

    PubMed  CAS  Google Scholar 

  75. Omura G, Ehrlich C, Blessing J: A randomized trial of cyclophosphamide plus adriamycin with or without cis-platinum in ovarian carcinoma. Proc ASCO 1:104, 1982.

    Google Scholar 

  76. Bradner W, Rose W, Huftalen J: Antitumor activity of platinum analog. Cisplatin: Current Status and New Developments, Academic Press, New York, 1980, pp 171–182.

    Google Scholar 

  77. Wolpert-DeFilippes M: Antitumor activity of cisplatin analogs. In: Cisplatin: Current and New Developments, Academic Press, New York, 1980, pp 183–191.

    Google Scholar 

  78. Harrap K, Jones M, Wilkinson R, Clink H, Sparrow S, Mitchley B, Clarke S, Veasey A: Antitumor toxic and biochemical properties of cisplatin and eight other platinum complexes. In Cisplatin: Current Status and New Development, Academic Press, New York, 1980.

    Google Scholar 

  79. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith E, Baker JM, Peckham MJ, Harrap KR: Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147, 1982.

    PubMed  CAS  Google Scholar 

  80. Wiltshaw E, Evans BD, Jones AC, Baker JW, Calvert AH: JM8, successor to cisplatin in advanced ovarian carcinoma? Lancet 1:587, 1983.

    PubMed  CAS  Google Scholar 

  81. Wiltshaw E, Evans B, Calvert A, Jones A: JM8 alone for previously untreated advanced ovarian carcinoma. Lancet 1:1110, 1983.

    Google Scholar 

  82. Creaven P, Mittleman A, Pendyala L, Tseng M, Pontes E, Spurelding M, Moayeir H, Madejeruiaz S: Phase I study of a new anti-neoplastic platinum analogue, cis-dichloro-trans-dihydroxy-bis (isopropyllamine) platinum (IV) (CHIP). Proc ASCO 1:22, 1982.

    Google Scholar 

  83. Creavan P, Allen L, Cohen M, Nelson R: Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724). Cancer Treat Rep 60:445–449, 1976.

    Google Scholar 

  84. Bruhl P, Gunther U, Hoefer-Janker H, Huls W, Scheef W, Vahlensieck, W: Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumors. Int J Clin Pharmacol Biopharm 14:29–39, 1976.

    CAS  Google Scholar 

  85. Konyves I, Nordenskjold B, Forshell G, Schryver A, Westerberg-Larsson H: Preliminary clinical and absorption studies with prednimustine in patients with mammary carcinoma. Eur J Cancer 11:841–844, 1975.

    PubMed  CAS  Google Scholar 

  86. Johnsson JE, Trope C, Mattsson W, Grundsell H, Aspergren K, Konyves I: Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma. Cancer Treat Rep 63:421–424, 1970.

    Google Scholar 

  87. Lundvall F: Treosulfan in the treatment of ovarian carcinoma. ACTA Obstet Gynecol Scand 52:Suppl 22, pp 3–11, 1973.

    Google Scholar 

  88. Larsen M: Treatment of ovarian carcinoma with treosulfan. ACTA Obstet Gynecol Scand 52:Suppl 22, pp 12–17, 1973.

    Google Scholar 

  89. Sorensen H: Ovarian carcinoma treatment with treosulfan. ACTA Obstet Gynecol Scand 52:Suppl 22, pp 18–30, 1973.

    Google Scholar 

  90. Fennelly J: Treosulfan (dihydroxybusulphan) in the management of ovarian carcinoma. Br J Obstet Gynecol 84:300–303, 1977.

    CAS  Google Scholar 

  91. Blom J, Blessing J, Mladineo J, Morgan C, Ehrlich C, Homesley H: Dianhydrogalactitol in the treatment of advanced gynecologic malignancies. Proc AACR-ASCO 21:416, 1980.

    Google Scholar 

  92. Crooke ST, Bradner WT: Mitomycin C: a review. Cancer Treat Rev 3:121–139, 1976.

    PubMed  CAS  Google Scholar 

  93. Shan M, Catalano R, Creech R: Phase II study of mitomycin in the treatment of advanced ovarian carcinoma. Proc ASCO 2:151, 1983.

    Google Scholar 

  94. Baker L, Izbricki R, Vaitkevicius V: Phase II study of porfiromycin versus mitomycin-C utilizing acute intermittent schedules. Med Pediatr Oncol 2:207–213, 1976.

    PubMed  CAS  Google Scholar 

  95. Von Hoff DD, Howser D, Gormley P et al.: Phase I study of 4’-(9-acridinylamino)-methanesulfon-m-anisidide in B16 melanoma. Pharmacology (Basel) 16:221–225, 1978.

    Google Scholar 

  96. Ahmann FR, Meyskens FL, Jr, Moon TE, Durie BG, Salmon SE: In vitro chemosensitivities of human tumor stem cells to the phase II drug 4’-(9-acrindinylamino) methanesulfon-m-anisidide and prospective in vivo correlations. Cancer Res 42:4494–4498, 1982.

    Google Scholar 

  97. Brenner DE, Garbino C, Kasdorf H, Villasanta U, Polcaro R, Yovarone J, Aisner J, Schiffer CA, Wiernik PH: A phase II trial of m-ASMA in the treatment of advanced gynecologic malignancies. AM J Clin Oncol 5:291–295, 1982.

    PubMed  CAS  Google Scholar 

  98. Dombernowsky P, Siengenthaler P, Somers R, Hansen HH: Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinoma. Eur J Clin Oncol 18:71–74, 1982.

    CAS  Google Scholar 

  99. Hilgers RD, Legha SS, Panettiers FJ, Alberts DS: m-AMSA inepithelial carcinoma of the ovary. A Southwest Oncology Group study. AM J Clin Oncol 6:277–279, 1983.

    PubMed  CAS  Google Scholar 

  100. Kearsley JH, Page JP, Levi JA, Woods RL, Tattersall MH, Fox RM, Coates AS: Meta AMSA (m-AMSA) in patients with advanced ovarian carcinoma. Aust NZ J Obstet Gynecol 22:107–109, 1982.

    CAS  Google Scholar 

  101. Von Hoff DD, Howser D, Gormley P, Bender RA, Glaubiger D, Levine AS, Young RC: Phase I study of methanesulfonamide, N-[4-(9-acrindinylamino)-3-methoxyphenyl]-(m-ASMA) using a single-dose schedule. Cancer Treat Rep 62:1421–1426, 1978.

    Google Scholar 

  102. Slayton R: Personal communication.

    Google Scholar 

  103. Miller TP, Jones SE, Chester A: Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid timors. Cancer Treat Rep 64:1001–1003, 1980.

    PubMed  CAS  Google Scholar 

  104. Skoda V, Jandova A, Novotna J: Comparison of cytostatic activities of cytembena and cyclophosphamide during short term administration to women with gynecological carcinoma. Neoplasm 17:175–181, 1970.

    CAS  Google Scholar 

  105. Edmonson JH, Decker DG, Malkasian GD, Webb MJ, Jorgensen EO: Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communication. J Natl Cancer Inst 59:1619–1620, 1977.

    PubMed  CAS  Google Scholar 

  106. Baker L, Samson M, Izbicki R: Phase II evaluation of Cytembena in disseminated epithelial ovarian cancers and sarcomas. Cancer Treat Rep 60:1389–1391, 1976.

    PubMed  CAS  Google Scholar 

  107. Novotna J, Andrysek O: Preliminary results with the new cytostatic Penberol in ovarian carcinoma. Neoplasma 27:77, 1982.

    Google Scholar 

  108. Novotna J, Andrysek O, Kobilkova J, Laurova L: Survival of patients with advanced ovarian carcinoma treated with Penberol. Neoplasm 30:245–250, 1983.

    CAS  Google Scholar 

  109. Dalton L, Demerac S, Elmes B, Loder J, Swan J, Teitei T: Synthesis of the tumor-inhibiting alkaloids ellipticine, 9-methoxy-ellipticine and related pyrido (4,36) carbazoles. Aust J Chem 20:2615–2727, 1967.

    Google Scholar 

  110. Mathi G, Hayat M, DeVassas F, Schwarzenberg L, Schneider M, Schlumberger J, Jasmin C, Rosenfield C: Methoxy-9-ellipticine lactate. III. Clinical screening: its action in acute myeloblastic leukemia. Rev Eur Etud Clin Biol 15:541–545, 1970.

    Google Scholar 

  111. Paoletti C, LePecq JB, DatXuong N, Juret P, Amiel JL, Rouesse J: Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264–137). Recent Results Cancer Res 74:107–123, 1980.

    PubMed  CAS  Google Scholar 

  112. Trope C: A phase II study of 4’-epi-doxorubicin ovarian carcinoma. Proc ASCO 1:121, 1982.

    Google Scholar 

  113. Ohnuma T, Sridhar KS, Ratner LH, Holland JH: Phase I study of indicine N-oxide in patients with advanced cancer. Cancer Treat Rep 66:1509–1515, 1982.

    PubMed  CAS  Google Scholar 

  114. Majima H: Exploratory study of macromomycin. Gan To Kagaku Ryoho 9:1568–1573, 1982.

    PubMed  CAS  Google Scholar 

  115. Slayton R, Creasman W, Petty W, Bundy B, Blessing J: Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group study. Cancer Treat Rep 63:2089–2092, 1979.

    PubMed  CAS  Google Scholar 

  116. Edmonson JH, Decker DG, Malkasian GD, Webb MJ, Jorgensen EO: Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents. Gynecol Oncol 6:7–9, 1978.

    PubMed  CAS  Google Scholar 

  117. Brenner DE, Jones HW, Rosenshein NB, Forasteiere A, Dillon M, Grumbine F, Tipping S, Burnett L, Grecto FA, Wiernik PH: Phase II evaluation of spirogermanium in advanced ovarian carcinoma. Cancer Treat Rep 67:193–194, 1983.

    PubMed  CAS  Google Scholar 

  118. Trope C, Mattson W, Gynning I, et al.: Phase II study of spirogermanium in advanced ovarian malignancy. Cancer Treat Rep 65:119–120, 1981.

    PubMed  CAS  Google Scholar 

  119. Slavik M, Muss H, Blessing JA, Delgado G: Phase II clinical study of Yoshi 864 in epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. Cancer Treat Rep 66:1775–1777, 1982.

    PubMed  CAS  Google Scholar 

  120. Omura G, DiSaia P, Blessing J, Boronow R, Hershchyshyn M, Park R: Chemotherapy for mustard-resistant ovarian adenocarcinoma: a randomized trial of CCNU and methyl-CCNU. Cancer Treat Rep 61:1533–1535, 1977.

    PubMed  CAS  Google Scholar 

  121. Muss H, Slavik M, Bundy B, Stehman F, Creasman W: A phase II study of PALA (NSC-224131) in patients with advanced ovarian carcinoma (a Gynecologic Oncology Group study). In press in Amer J Clin Oncol.

    Google Scholar 

  122. Thigpen T, Ehrlich C, Creasman W, Curry S, Blessing J: Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. Amer J Clin Oncol 6:273–275, 1983.

    CAS  Google Scholar 

  123. Muss H: Personal communication.

    Google Scholar 

  124. Thigpen T, Blessing J, Arseneau J, Homesley H: Phase II trial of piperazinedione (NSC-135758) in the treatment of advanced or recurrent carcinoma of tfie ovary. In press in Amer J Clin Oncol.

    Google Scholar 

  125. Arseneau J, Bundy B, Homesley H, Beecham J: Phase II STUDY OF Baker’s Antifolin advanced carcinoma of the ovary. Invest New Drugs 1:185–188, 1983.

    PubMed  CAS  Google Scholar 

  126. Gralla RJ, Tan CT, Young CW: Phase I trial of chlorozotocin. Cancer Treat Rep 63:17–20, 1979.

    PubMed  CAS  Google Scholar 

  127. Friedman M, Hoffman P, Jones H: Hormone receptor assays in malignant disease. Cancer Treat Rep 5:185–194, 1978.

    CAS  Google Scholar 

  128. Mishell DR, Jr: Noncontraceptive heath benefits of oral steroidal contraceptives. Am J Obstet Gynecol 142:809–816, 1982.

    PubMed  Google Scholar 

  129. Jolles B: Progestins in the Treatment of advanced malignant tumors of breast, ovary, and uterus. BR J Cancer 16:209, 1962.

    PubMed  CAS  Google Scholar 

  130. Varza A, Henriksen E: Effect of 17-hydroxyprogesterone-17-n-caproate on various pelvic malignancies. Obstet Gynecol 23:51, 1964.

    Google Scholar 

  131. Ward HW: Progestogen therapy for ovarian carcinoma. J Obstet Gynecol Br Commonw 79:555–559, 1979.

    Google Scholar 

  132. Timothy I: Progestogen therapy for ovarian carcinoma. Br J Obstet Gynecol 89:561–563, 1982.

    CAS  Google Scholar 

  133. Kaufman RJ: Management of advanced ovarian carcinoma. Med Clin North Am 50:845, 1966.

    PubMed  CAS  Google Scholar 

  134. Malkasian GD, Jr, Decker DG, Jorgensen EO, Webb MJ: 6-Dehydro-6 17 alpha-dimethyl-progesterone (NSC-123018) for the treatment of metastatic and recurrent ovarian carcinoma. Cancer Chemother Rep 57:241–242, 1973.

    PubMed  Google Scholar 

  135. Malkasian GD, Jr, Decker DG, Jorgensen EO, edmonson JH: Medroxyprogesterone acetate for the treatment of metastatic and recurrent ovarian carcinoma. Cancer Treat Rep 61:913–914, 1977.

    PubMed  Google Scholar 

  136. GalloCurcia C, Casalai A, Gianciotta A, Gionfra T, Rhinaldi M, Terzoli L, Orofino G: Chemo-hormonotherapeutic treatment of 20 cases of metastatic ovarian carcinoma. Clin Ter 90:137–142, 1979.

    Google Scholar 

  137. Aabo K, Pedersen AG, Haid I, Dombernowsky P: High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: a phase II study. Cancer Treat Rep 66:407–408, 1982.

    PubMed  CAS  Google Scholar 

  138. Trope C, Johnsson JE, Sigurdsson K, Simonsen E: High-dose medroxyprogesterone acetate for the treatment of advanced ovarian carcinoma. Cancer Treat Rep 66:1441–1443, 1982.

    PubMed  CAS  Google Scholar 

  139. Geisler HE: Megestrol acetate for the palliation of advanced ovarian carcinoma. Obstet Gynecol 61:95–98, 1983.

    PubMed  CAS  Google Scholar 

  140. Taznon H: Antiestrogens in treatment of breast cancer. Cancer 39:2959, 1977.

    Google Scholar 

  141. Myers M, Moore GE, Major FJ: Advanced ovarian carcinoma: response to antiestrogen therapy. Cancer 48:2368–2370, 1981.

    PubMed  CAS  Google Scholar 

  142. Schwartz P, Renting G, Maclusky N, Naftolin F, Eisenfeld A: Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 59:583–588, 1982.

    PubMed  CAS  Google Scholar 

  143. Lazlo J, Schwartz P, Maclusky N, Eisenfeld A: In vitro responsiveness of ovarian epithelial carcinomato tamoxifen. Proc ASCO 2:153, 1983.

    Google Scholar 

  144. Golumb HM, Thompson S: Estrogen receptor. Therapeutic guide in an undifferentiated metastatic carcinoma in women. Arch Intern Med 135:942, 1975.

    Google Scholar 

  145. Martin JD, Hahnel R: Estrogen receptor studies in carcinoma of the endometrium, carcinoma of the uterine cervix and other gynecological malignancies. Aust NZ J Obstet Gynecol 18:55–59, 1978.

    CAS  Google Scholar 

  146. Holt J, Caputo T, Kelley K, et al.: Estrogen and progesterone binding in cytosols of ovarian adenocarcinoma. Obstet Gynecol 53:50–58, 1979.

    PubMed  CAS  Google Scholar 

  147. Janne O, Kauppila A, Syrjala P, Vihko R: Comparison of cytosol estrogen and progestin receptor status in malignant and benign tumors and tumor-like lesions of human ovary. Int J Cancer 25:175–179, 1980.

    PubMed  CAS  Google Scholar 

  148. Kauppila A, Vierikko P, Kivinen S, Stenback F, Vihko R: Clinical significance of estrogen and progestin receptors in ovarian cancer. Obstet Gynecol 61:320–326, 1983.

    PubMed  CAS  Google Scholar 

  149. Jones L, Jolies C, Edwards C, Freedman R, Gallager H: Estrogen and progesterone receptors in advanced ovarian carcinoma. Proc AACR 24:176, 1983.

    Google Scholar 

  150. Leibach S, Miller N, Slayton R, Graha J, Miller A, Yordan E, Wilbanks G, Dunne C: Hormone receptors in ovarian carcinoma. Proc AACR 24:176, 1983.

    Google Scholar 

  151. Pollow K, Schmidt-Matthiesen A, Hoffman G, Schweikhart G, Kreinberg R, Manz B, Grill HJ: 3H-estradiol and 3H-R5020 binding in cytosols of normal and neoplastic human ovarian tissue.

    Google Scholar 

  152. Jolies CJ, FriFreidman RS, Jones LA: Estrogen and progestogen therapy in advanced ovarian cancer: preliminary report. Gynecol Oncol 16:352–359, 1983.

    Google Scholar 

  153. Lele SB, Piver MS, Barlow JJ, Chatterjee S, Schneider S, Ip M: Comparison of cytosol estrogen receptor status in ovarian carcinoma using different radiolabeled ligands and methods. J Surg Oncol 21:155–158, 1982.

    PubMed  CAS  Google Scholar 

  154. Creasman WT, Sasso RA, Weed JC, Jr, McCarty KS, Jr: Ovarian carcinoma: histologic and clinical correlation of cytoplasmic estrogen and progesterone binding. Gynecol Oncol 12:319–327, 1981.

    PubMed  CAS  Google Scholar 

  155. Freidman M, Lazios M, Markowitz A, Jones H, Resser K, Hoffman P: Estradiol and progesterone receptors in ovarian cancer-clinical and pathological correlation. Clin Res 27:385A, 1979.

    Google Scholar 

Download references

Authors
  1. J. Tate Thigpen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine Section of Hematology & Oncology, University of Arizona Health Sciences Center, Tucson, Arizona, USA

    David S. Alberts

  2. Department of Obstetrics & Gynecology, University of Arizona Health Sciences Center, Tucson, Arizona, USA

    Earl A. Surwit

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Thigpen, J.T. (1985). Single agent chemotherapy in the management of ovarian carcinoma. In: Alberts, D.S., Surwit, E.A. (eds) Ovarian Cancer. Cancer Treatment and Research, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2561-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2561-1_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9609-6

  • Online ISBN: 978-1-4613-2561-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation